PIG
ADVM

Pantheon Investment Group’s Adverum Biotechnologies ADVM Stock Holding History

Pantheon Investment Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-150
Closed -$1K – 68
2020
Q4 		$1K Sell
150
-50
-25% -$6.19K ﹤0.01% 69
2020
Q3 		$4K Buy
+200
New +$30K ﹤0.01% 62

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pantheon Investment Group's ADVM Position: Q2 2021 in Review

Pantheon Investment Group sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 7,278 shares — an estimated $718K sold.

Pantheon Investment Group first reported a position in ADVM in Q3 2020 and held it in 3 quarters. The position peaked at $767K in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Pantheon Investment Group reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Pantheon Investment Group sold 7,278 Adverum Biotechnologies shares in Q2 2021, an estimated $718K.
  • Pantheon Investment Group first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 3 quarters.
  • Pantheon Investment Group's Adverum Biotechnologies position peaked at $767K in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Pantheon Investment Group's 13F filing for Q2 2021, filed 23 Aug 2021.